Pal SK - Search Results

1

Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.

Chehrazi-Raffle A, Leong S, Ali S, Kim T, Melamed S, Li X, Zengin Z, Meza L, Chawla N, Govindarajan A, Castro D, Mercier B, Ebrahimi H, Dizman N, Tripathi N, Sayegh N, Rock A, Yeh J, Pal SK, Onyshchenko M. Chehrazi-Raffle A, et al. Among authors: pal sk. Oncologist. 2023 Dec 11;28(12):1079-1084. doi: 10.1093/oncolo/oyad190. Oncologist. 2023. PMID: 37432304 Free PMC article.

2

Adjuvant therapy for renal cell carcinoma: past, present, and future.

Pal SK, Haas NB. Pal SK, et al. Oncologist. 2014 Aug;19(8):851-9. doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26. Oncologist. 2014. PMID: 24969163 Free PMC article. Review.

3

Advances in treatment of metastatic renal cell carcinoma.

Gong J, Gerendash B, Dizman N, Khan A, Pal SK. Gong J, et al. Among authors: pal sk. Curr Opin Urol. 2016 Sep;26(5):439-46. doi: 10.1097/MOU.0000000000000319. Curr Opin Urol. 2016. PMID: 27467136 Review.

4

Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar.

Pal SK, Agarwal N, Dizman N, Sonpavde G. Pal SK, et al. Lancet Oncol. 2016 Nov;17(11):1477-1478. doi: 10.1016/S1470-2045(16)30493-4. Epub 2016 Oct 3. Lancet Oncol. 2016. PMID: 27720137 No abstract available.

5

Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.

Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ. Pal SK, et al. Clin Genitourin Cancer. 2017 Aug;15(4):e573-e582. doi: 10.1016/j.clgc.2016.12.005. Epub 2017 Jan 5. Clin Genitourin Cancer. 2017. PMID: 28139444 Free article.

6

Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?

Pal SK, Maia MC, Dizman N, Agarwal N. Pal SK, et al. Eur Urol. 2017 Dec;72(6):972-973. doi: 10.1016/j.eururo.2017.03.006. Epub 2017 Mar 15. Eur Urol. 2017. PMID: 28314610 No abstract available.

7

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK. Pal SK, et al. Eur Urol. 2017 Oct;72(4):557-564. doi: 10.1016/j.eururo.2017.03.046. Epub 2017 Apr 14. Eur Urol. 2017. PMID: 28413127

8

Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors.

Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N. Bailey EB, et al. Among authors: pal sk. J Oncol Pharm Pract. 2018 Apr;24(3):190-197. doi: 10.1177/1078155217693426. Epub 2017 Feb 20. J Oncol Pharm Pract. 2018. PMID: 28436250

9

Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma.

Maia MC, Bergerot P, Pal SK. Maia MC, et al. Among authors: pal sk. Eur Urol Focus. 2016 Dec 15;2(6):579-581. doi: 10.1016/j.euf.2017.02.008. Epub 2017 Mar 1. Eur Urol Focus. 2016. PMID: 28723488

10

Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.

Dizman N, Bergerot P, Bergerot C, Lanman RB, Raymond VM, Banks KC, Jones J, Pal SK. Dizman N, et al. Among authors: pal sk. Eur Urol. 2018 Feb;73(2):308-310. doi: 10.1016/j.eururo.2017.08.006. Epub 2017 Aug 24. Eur Urol. 2018. PMID: 28844598 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,149 results

Search Page

Filters